Wed, Jul 23, 2014, 7:49 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Neurocrine Biosciences Inc. Message Board

  • jb108 jb108 Sep 11, 2013 12:30 PM Flag

    looks like the bottom is here

    don't forget that higher doses are very effectiver

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I think that point is completely missed by the world. The 100 mg dose is great. They really should have written the release different and said the 100 mg dose was proven effective and the 50 was not so the forge on with the 100 mg. Can't believe the drop as this is not a failure of the drug. I just am taking advantage of it.

      My best,

      John

      • 2 Replies to jonofdubln
      • I won't be surprised if this was done deliberately. The insiders know what they have in their cards, so the market can drop the pps 30% and it won't rattle them a bit, because of their confidence in their product. The retail trader/investor who is just trying to catch a ride in the momentum of a rising stock without the knowledge of the science are the ones who will sell with a drop like this. Especially to the ones using margin. The insiders /CEO knew what he was doing exactly. To the ones who knows the science, hold tight, and if it drops below $11.50....buy some more if you have the resources.

        Sentiment: Hold

      • John,

        This is the second failure of a VMAT2 trial and brings into question whether O'Brien et al can run a succesful trial. Keep in mind that the on site AIMS evaluators they are now blaming were selected and trained by Neurocrine. When Abbott first partnered with Neurocrine they couldn't wait to pry Elagolix away from them, because they saw Neurcrine's drug development plan as fatally flawed. JMO.

        Ochs

 
NBIX
13.71+0.16(+1.18%)Jul 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.